INMAXX

This brand name is authorized in Ecuador

Active ingredients

The drug INMAXX contains a combination of these active pharmaceutical ingredients (APIs):

1 Silymarin
UNII U946SH95EE - MILK THISTLE

Silymarin is a plant-derived flavonoid from the plant Silybum marianum. The main component of the silymarin complex is silybin, which is a mixture of two diastereomers A and B in approximately 1:1 proportion. The drug possess hepatoprotective and antioxidant activity. The hepatoprotective effect is due to stimulation of synthesis of structural and functional proteins and phospholipids, as well as acceleration of the regeneration of hepatocytes. Antioxidant effect is determined by interaction of bioflavones with free radicals in the liver and its detoxication. In such manner the process of peroxidation of the lipids is interrupted and further liver destruction is prevented.

Read about Silymarin
2 Ubidecarenone
UNII EJ27X76M46 - UBIDECARENONE
Read about Ubidecarenone
3 Vitamin B1
UNII M572600E5P - THIAMINE HYDROCHLORIDE

Thiamine pyrophosphate (TPP), the coenzymatic form of thiamine, is involved in two main types of metabolic reactions: decarboxylation of ฮฑ-ketoacids (e.g. pyruvate, ฮฑ-ketoglutarate and branched-chain keto acids) and transketolation (e.g. among hexose and pentose phosphates). Therefore, the principal physiological role of thiamine is as a coenzyme in carbohydrate metabolism, where TPP is required for several stages in the breakdown of glucose to provide energy.

Read about Vitamin B1
4 Pyridoxine
UNII 68Y4CF58BV - PYRIDOXINE HYDROCHLORIDE

Pyridoxine hydrochloride is Vitamin B6. It is converted to pyridoxal phosphate which is the co-enzyme for a variety of metabolic transformations. It is essential for human nutrition.

Read about Pyridoxine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
A05BA03 Silymarin A Alimentary tract and metabolism → A05 Bile and liver therapy → A05B Liver therapy, lipotropics → A05BA Liver therapy
Discover more medicines within A05BA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EC Agencia Nacional de Regulaciรณn, Control y Vigilancia Sanitaria Identifier(s): 971-MEN-0117

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.